Cited 147 times in
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정민규 | - |
dc.date.accessioned | 2015-01-06T17:30:03Z | - |
dc.date.available | 2015-01-06T17:30:03Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100096 | - |
dc.description.abstract | PURPOSE: Genexol-PM is a Cremorphor EL (CrEL)-free polymeric micelle formulation of paclitaxel that allows higher-dose administration with less hypersensitivity. This study was designed to evaluate the efficacy and safety of Genexol-PM and gemcitabine combination in advanced non-small cell lung cancer patients as a first-line treatment. PATIENTS AND METHODS: This is a prospective, single-arm, single-center phase II study. Patients with advanced NSCLC received Genexol-PM at 230 mg/m(2) on day 1 and gemcitabine 1,000 mg/m(2) on day 1 and day 8 of a 3-week cycle. Six cycles of chemotherapy were planned unless there was disease progression. The primary endpoint was overall response rate. RESULTS: Forty-three patients received the study drugs with a median of 4 cycles per patient (range 1-6). The overall response rate was 46.5%. The median progression-free survival was 4.0 months (95% CI 2.0-6.0 months), and median overall survival was 14.8 months (95% CI 9.1-20.5 months). The most common toxicities were anemia (n = 29, 67%), asthenia (n = 17, 40%), myalgia (n = 16, 37%), peripheral neuropathy (n = 15, 35 %), and diarrhea (n = 12, 30%). The most common grade 3/4 adverse events were neutropenia (n = 7, 16%) and pneumonia (n = 5, 12%). Two patients died of pneumonia and dyspnea. CONCLUSIONS: CrEL-free paclitaxel in combination with gemcitabine demonstrated favorable antitumor activity with little emetogenicities in non-small cell lung cancer patients. However, frequent grade 3/4 toxicities were observed, and safety should be evaluated thoroughly in future studies. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 277~282 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/pathology | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/mortality | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology | - |
dc.subject.MESH | Carcinoma, Squamous Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality | - |
dc.subject.MESH | Carcinoma, Squamous Cell/pathology | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liposomes | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Nanoparticles/chemistry | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Young Adult | - |
dc.title | A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hee Kyung Ahn | - |
dc.contributor.googleauthor | Minkyu Jung | - |
dc.contributor.googleauthor | Sun Jin Sym | - |
dc.contributor.googleauthor | Dong Bok Shin | - |
dc.contributor.googleauthor | Shin Myung Kang | - |
dc.contributor.googleauthor | Sun Young Kyung | - |
dc.contributor.googleauthor | Jeong-Woong Park | - |
dc.contributor.googleauthor | Sung Hwan Jeong | - |
dc.contributor.googleauthor | Eun Kyung Cho | - |
dc.identifier.doi | 10.1007/s00280-014-2498-5 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03606 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 24906423 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-014-2498-5 | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Paclitaxel | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Genexol-PM | - |
dc.contributor.alternativeName | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Jung, Min Kyu | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 74 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 277 | - |
dc.citation.endPage | 282 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.74(2) : 277-282, 2014 | - |
dc.identifier.rimsid | 50136 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.